Conduct study P215

Ended Awarded Last action

Contract number
75N93021F00001
Awardee
Awarding agency
Obligated
$1,538,009

Award facts

Opportunity
Contract value 81% obligated
  • $1,538,009.00 Current, with exercised options
  • $1,887,979.00 Potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
Pricing
Cost Plus Fixed Fee
Place of performance
Rockville, MD 20850, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00008 $0
Other Administrative Action P00007 $0
Exercise an Option P00006 $532,654
Change Order P00005 $65,521
Funding Only Action P00004 $251,179
Other Administrative Action P00003 $0
Change Order P00002 $157,696
Change Order P00001 $0
Original award $530,959

About this award

The National Institute of Allergy and Infectious Diseases (NIAID) awarded Bioqual, Inc. a delivery order valued at $1.89M for conducting Study P215 under the Simian Vaccine Evaluation Units (SVEUS) program. This contract, which commenced on September 8, 2021 and is scheduled for completion by August 25, 2026, employs a cost-plus-fixed-fee pricing structure and is not set aside for any particular business category. The work will be performed in Potomac, Maryland, and represents a task order against NIAID's broader SVEUS indefinite delivery contract vehicle focused on developing and evaluating animal models for infectious disease countermeasures.

Bioqual, a Rockville-based biomedical research services company with extensive experience supporting federal research agencies since 1999, is well-positioned to execute this assignment. The company specializes in providing advanced preclinical research support, including non-human primate studies essential to vaccine development and infectious disease research. This delivery order aligns with NIAID's mission to support critical research infrastructure for evaluating potential medical countermeasures through sophisticated animal model systems, and reflects Bioqual's established expertise in conducting specialized studies involving primate research and laboratory analysis for the institute.

Quick answers

Who was awarded contract 75N93021F00001?

75N93021F00001 was awarded to Bioqual, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 8, 2021.

How much is contract 75N93021F00001 worth?

The government has obligated $1,538,009 on 75N93021F00001. Its potential value, with all options, is $1,887,979.

Is contract 75N93021F00001 an order under another contract?

Yes. 75N93021F00001 is a delivery order under 75N93020D00006, an indefinite delivery contract, on Simian Vaccine Evaluation Units.

Was contract 75N93021F00001 competed?

The extent of competition for 75N93021F00001 was full and open competition. The government received 3 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award